This study aims to design and improve tools that can be used to select strategies for improving colorectal cancer screening in different settings and populations. Interviews, surveys, and focus groups will be conducted with individuals who make decisions related to colorectal cancer screening interventions about their understanding, preferences, and suggestions related to these tools and intervention strategies.

The purpose of this study is to understand how your gut plays a role in how well CAR T cell therapy works. Your gut is home to bacteria, which we call the gut microbiome. The gut microbiome can send signals to your immune cells, which may impact how well and how long CAR T cell therapy will last. We can find out what type of bacteria are in your gut microbiome by studying your stool. We can understand more about the signals sent to the immune system by studying your blood. We will ask for stool and blood at the same time points throughout your treatment. We will study the identities and function of the bacteria and immune cells to understand more about how these signals work during CAR T cell treatment.

To find out if the addition of 2 blocks of inotuzumab ozogamicin to the standard chemotherapy regimen will improve outcomes in children and young adults with High-Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL).

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.

To create digital tools to support young adult cancer survivors completing active treatment and transitioning into survivorship care.

This phase 3 trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin and vincristine are chemotherapy drugs that work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. The overall goal of this study is to see if selumetinib works just as well as the standard treatment of CV for patients with LGG. Another goal of this study is to compare the effects of selumetinib versus CV in subjects with LGG to find out which is better. Additionally, this trial will

This study will evaluate the use of MMUD PBSC in adults and explore the safety and efficacy of MMUD BM in pediatric recipients with hematological malignancies who may lack other donor options.

The purpose of this research study is to create a Lymphoma Registry of patients who are willing to complete the study's comprehensive assessment. The assessment is designed to gather information on memory, nutritional status, mental health, and level social support. It is also designed to understand how well you carry out your day to day activities and to briefly describe what other medical conditions you may have. This assessment will help your health care team determine your "functional age" (the age you function at) as compared to how many years old you are. We will also ask you to complete questionnaires that ask questions about your personal health history, such as exercise and smoking,

Better understand symptoms that occur after liver-directed treatments for liver cancer

The purpose of this study is to develop a prospective longitudinal cohort/registry of lymphoma patients in Malawi to address a lack of prospective longitudinal data related to lymphoma in sub-Saharan Africa, and to serve as a foundation for developing optimal treatment strategies in this challenging environment.